证券代码：002915 证券简称：中欣氟材 公告编号：2025-023 浙江中欣氟材股份有限公司 关于提请股东大会授权董事会以简易程序 向特定对象发行股票的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江中欣氟材股份有限公司（以下简称"中欣氟材"或"公司"）于 2025 年 4 月 18 日分别召开了第六届董事会第二十次会议和第六届监事会第十七次会议，审 议通过了《关于提请股东大会授权董事会以简易程序向特定对象发行股票的议 案》。根据《上市公司证券发行注册管理办法》《深圳证券交易所上市公司证券 发行上市审核规则》《深圳证券交易所上市公司证券发行与承销业务实施细则》 等相关规定，公司董事会提请 2024 年年度股东大会授权董事会办理以简易程序 向特定对象发行融资总额不超过人民币 3 亿元且不超过最近一年末净资产 20% 的股票，授权期限为公司 2024 年年度股东大会通过之日起至 2025 年年度股东大 会召开之日止。上述事项尚需提交股东大会审议。现将有关情况公告如下： 一、具体内容 （一）确认公司是否符合以简易程序向特定对象发行股票的条件 授权董事会 ...

Financial Performance - The company's operating revenue for 2024 was CNY 1,404,478,358.56, representing a 4.54% increase compared to CNY 1,343,528,068.38 in 2023[22]. - The net profit attributable to shareholders was a loss of CNY 185,526,314.34 in 2024, a slight improvement of 1.41% from a loss of CNY 188,179,014.98 in 2023[22]. - The cash flow from operating activities improved significantly, with a net outflow of CNY 74,765,694.92 in 2024, a 62.46% reduction from CNY 199,141,335.95 in 2023[22]. - The basic earnings per share for 2024 was -CNY 0.5682, showing a 0.98% improvement from -CNY 0.5738 in 2023[22]. - Total assets at the end of 2024 were CNY 3,193,122,766.38, a marginal increase of 0.06% from CNY 3,191,156,380.44 at the end of 2023[22]. - The company's net assets attributable to shareholders decreased by 12.49% to CNY 1,298,772,126.57 at the end of 2024, down from CNY 1,484,092,908.60 at the end of 2023[22]. - The company reported a significant loss in the fourth quarter, with a net profit attributable to shareholders of -CNY 142,531,581.18[27]. - The company achieved operating revenue of ¥1,404,478,358.56, an increase of 4.54% year-on-year[114]. - The net profit attributable to shareholders was -¥185,526,314.34, a year-on-year reduction in losses of ¥2,652,700.64[114]. Business Operations and Strategy - The company has focused on the production and R&D of fluorine-containing pharmaceutical, pesticide, and electronic material intermediates since its establishment in 2000[20]. - The company operates in the fine chemical manufacturing industry, specifically in the fluorine chemical sector[20]. - The company aims to achieve a 100% phase-out of second-generation refrigerants in the domestic market within the next five years and an 80% phase-out of third-generation refrigerants in developed countries within the next ten years[88]. - The company is actively seeking new markets and customers internationally while solidifying its existing domestic and foreign markets[90]. - The company is committed to developing functional fluorinated new materials and electronic new materials in niche markets[89]. - The company is focusing on the development of new technologies and products in the fluorine chemical sector to enhance its market position[169]. - The company is actively pursuing market expansion and strategic acquisitions to strengthen its competitive edge in the chemical industry[169]. - The company aims to become a leading domestic fluorochemical enterprise with a focus on high-end fluorine materials and a complete industrial chain by the end of 2025[172]. Research and Development - The company has maintained an annual R&D investment of approximately 4% of sales revenue, with a total of 5 invention patents and 13 utility model patents applied for during the reporting period[106]. - The company invested ¥4,309.09 million in R&D in 2024, accounting for 3.07% of total revenue, focusing on new materials and new energy technologies[121]. - The number of R&D personnel rose by 62.16% from 74 in 2023 to 120 in 2024, with a significant increase in the proportion of personnel holding bachelor's degrees by 40%[148]. - The company has developed a new synthesis process for BMMI products, improving yield and quality significantly[100]. - The company is focusing on the development of new energy electronic chemicals, including sodium hexafluorophosphate and lithium bis(fluorosulfonyl)imide, which will significantly enhance product technical content and added value[108]. Market Trends and Industry Outlook - The fluorochemical industry is projected to grow from CNY 178 billion in 2016 to CNY 323 billion by 2025, with a compound annual growth rate of 6.9%[35]. - The pharmaceutical intermediate market in China is expected to reach CNY 255.2 billion in 2024, growing at a rate of 5.45%[39]. - The global market for fluorinated pharmaceutical intermediates has been continuously growing, driven by the increasing number and proportion of fluorinated drugs, particularly in the oncology and antiviral sectors[46]. - The market for fluorinated pesticide intermediates in China reached approximately 12 billion yuan in 2023, with a year-on-year growth of 8%[57]. - The global high-performance polymer market is projected to reach $49.14 billion in 2024, with a compound annual growth rate of 8.4% from 2024 to 2029, indicating strong demand in various industries[58]. Financial Management and Governance - The company has established a governance structure that complies with relevant laws and regulations, ensuring the protection of shareholder rights[187]. - The company has implemented safety measures to mitigate risks associated with the production of flammable and toxic chemicals, although safety incidents remain a concern[181]. - The company has confirmed that there are no significant discrepancies between its governance practices and regulatory requirements[194]. - The company has established an independent financial accounting department and developed a financial management system compliant with accounting standards[198]. - The company has independent personnel management systems, ensuring that senior management does not hold positions in other companies controlled by the major shareholder[197]. Challenges and Risks - The company faces challenges from high raw material prices and a decline in product prices, impacting gross margins and operating rates[114]. - The company is exposed to raw material price volatility, which significantly affects its operating costs and profit margins[182]. - The company's customer base is concentrated in the pharmaceutical and fluorochemical sectors, with major clients including Jingxin Pharmaceutical and Zhejiang Medicine, which poses a risk if any major client faces operational difficulties[180]. - The company is facing risks related to the concentration of its products in the pharmaceutical and pesticide intermediate sectors, which could impact performance if market conditions change[180]. Environmental and Social Responsibility - The company has invested over 100 million yuan in environmental protection measures, ensuring compliance with national standards for waste emissions[181]. - The company is committed to enhancing investor relations and maintaining a positive capital image through effective communication and transparency[178].

Financial Performance - The company's revenue for Q1 2025 was CNY 355,744,197.67, representing an increase of 11.97% compared to CNY 317,726,775.95 in the same period last year[5] - Net profit attributable to shareholders was CNY 3,115,476.97, up 22.00% from CNY 2,553,569.05 year-on-year[5] - The net profit after deducting non-recurring gains and losses increased by 76.62% to CNY 2,644,913.24 from CNY 1,497,530.88 in the previous year[5] - The company experienced a 38.90% decrease in total profit, amounting to CNY 5,298,035.68, attributed to rising sales, management, and financial expenses[8] - Total operating revenue for the current period reached ¥355,744,197.67, an increase of 11.96% compared to ¥317,726,775.95 in the previous period[16] - Total operating costs amounted to ¥346,879,680.65, up from ¥303,384,589.00, reflecting a growth of 14.34%[16] - Net profit attributable to the parent company was ¥3,115,476.97, a significant increase of 22.06% from ¥2,553,569.05 in the prior period[17] - The basic and diluted earnings per share improved to ¥0.0096 from ¥0.0078, an increase of 23.08%[17] Cash Flow and Liquidity - The company's cash flow from operating activities showed a significant decline, with a net outflow of CNY 22,143,867.22 compared to a net inflow of CNY 7,179,218.34 in the same period last year, a decrease of 408.44%[5] - Cash flow from operating activities showed a net outflow of ¥22,143,867.22, contrasting with a net inflow of ¥7,179,218.34 in the previous period[18] - Cash and cash equivalents decreased to CNY 207,811,397.68 from CNY 250,629,277.56[13] - Cash and cash equivalents at the end of the period totaled ¥156,069,317.69, down from ¥209,984,130.35, indicating a decrease of 25.6%[19] - The company reported a net cash outflow from investing activities of ¥10,836,260.44, compared to a larger outflow of ¥152,485,194.09 in the previous period[18] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,236,115,236.30, reflecting a 1.35% increase from CNY 3,193,122,766.38 at the end of the previous year[5] - The company reported a total asset of CNY 3,236,115,236.30 as of March 31, 2025, an increase from CNY 3,193,122,766.38 at the beginning of the period[13] - Current assets totaled CNY 982,407,766.53, slightly up from CNY 977,915,978.58 at the start of the period[13] - Total liabilities amounted to CNY 1,693,720,736.77, up from CNY 1,657,356,153.72, showing an increase of approximately 2.2%[14] - The company’s long-term borrowings increased to CNY 391,521,065.49 from CNY 338,874,602.41, representing a growth of approximately 15.5%[14] - The total liabilities and equity reached ¥3,236,115,236.30, an increase from ¥3,193,122,766.38, representing a growth of 1.35%[15] Research and Development - The company's R&D expenses surged by 138.41% to CNY 13,840,110.45, primarily due to increased projects in subsidiaries[8] - Research and development expenses surged to ¥13,840,110.45, compared to ¥5,805,219.20, marking an increase of 138.79%[16] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 28,620, with the largest shareholder holding 19.97% of the shares[9] - The company's equity increased significantly, with retained earnings rising to CNY 3,793,308.29 from CNY 677,831.32, marking a substantial growth[14] Other Information - The company decided to terminate the plan for issuing shares to specific targets for the year 2024[11] - The first quarter report of Zhejiang Zhongxin Fluorine Material Co., Ltd. is unaudited[20] - The new accounting standards will be implemented starting from 2025[20] - The financial statement items related to the first year of the new accounting standards will be adjusted at the beginning of the year[20] - The board of directors announced the first quarter report on April 18, 2025[20] - There are no specific performance summaries or user data provided in the document[20] - Future outlook and performance guidance are not detailed in the content[20] - No information on new products or technology development is mentioned[20] - Market expansion and mergers or acquisitions are not addressed in the document[20] - Other new strategies are not discussed in the content[20] - The document does not provide any financial figures or percentages[20]

Investment Rating - The report maintains a rating of "Accumulate" for the company [5] Core Views - The company's gross margin is under pressure due to declining product prices and goodwill impairment, leading to a forecasted net profit loss for 2024 [1] - The company is expected to generate revenue between 1.4 billion to 1.42 billion yuan in 2024, with a projected net loss of 200 million to 180 million yuan [1] - The company has a complete fluorochemical industry chain, expanding from traditional pharmaceutical and pesticide sectors to new materials [2] - The recovery in the pesticide industry is anticipated to stabilize product prices and improve profitability [2] - The company’s profitability is expected to gradually recover as downstream demand increases and new production capacities are released [3] Summary by Sections Financial Performance - In 2024, the company is projected to have a revenue of 1.418 billion yuan, a slight increase from 1.344 billion yuan in 2023, but a significant drop in net profit to -192 million yuan [4][8] - The gross margin is expected to decline to 7.7% in 2024 from 13.6% in 2023 [10] - The company’s earnings per share (EPS) is forecasted to be -0.59 yuan in 2024, compared to -0.57 yuan in 2023 [4][10] Production Capacity and Market Outlook - New production capacities for fluorobenzene, fluoroketone, and electronic-grade hydrogen fluoride are expected to come online, but low utilization rates may hinder profitability [1][2] - The company is planning to write down goodwill for its subsidiaries, which will impact overall performance [1] Valuation Metrics - The report projects a decline in net profit for 2024, with subsequent recovery expected in 2025 and 2026, forecasting net profits of 28 million and 75 million yuan respectively [3][4] - The price-to-earnings (P/E) ratio is expected to be 50 in 2026, indicating a potential recovery in profitability [10][11]

Group 1 - The company disclosed that as of February 10, the number of shareholders was 31,292, a decrease of 1,960 from the previous period (January 31), representing a month-on-month decline of 5.89% [1] - On January 18, the company released a 2024 earnings forecast, expecting a net profit loss between 200 million and 180 million yuan [1]

证券代码：002915 证券简称：中欣氟材 公告编号：2025-008 浙江中欣氟材股份有限公司 关于使用闲置自有资金进行现金管理到期赎回 并继续进行现金管理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江中欣氟材股份有限公司（以下简称"公司"）于 2024 年 4 月 12 日分别 召开了第六届董事会第十四次会议和第六届监事会第十二次会议，审议通过了 《关于公司及子公司使用部分闲置自有资金进行现金管理的议案》，同意公司使 用最高额度不超过人民币 10,000 万元的闲置自有资金在确保不影响日常经营资 金需求和资金安全的情况下进行现金管理，适时用于购买安全性高、流动性好、 保本型等金融机构理财产品。使用期限自公司董事会审议通过之日起 12 个月内 有效，在上述额度范围内资金可以滚动使用，该事项无需提交股东大会审议。公 司监事会对上述事项发表了明确同意的意见，具体内容详见公司于 2024 年 4 月 16 日在《证券时报》《证券日报》《中国证券报》《上海证券报》和巨潮资讯 网（http://www.cninfo.com.cn）上披露的《关于公司及子公 ...

Core Viewpoint - The company, Zhongxin Fluorine Materials (002915.SZ), is forecasting a net loss for 2024, with expected losses between 180 million to 200 million yuan, compared to a loss of 188.18 million yuan in the previous year [1][5]. Financial Performance - The projected net profit attributable to shareholders is expected to be a loss of 180 million to 200 million yuan, while the previous year's loss was 188.18 million yuan [1][5]. - The net profit after excluding non-recurring gains and losses is anticipated to be a loss of 166.5 million to 185 million yuan, compared to a loss of 179.13 million yuan in the previous year [1][5]. - The basic earnings per share are expected to be a loss of 0.5506 to 0.6118 yuan, compared to a loss of 0.5738 yuan in the previous year [1][5]. - The projected operating revenue is expected to be between 1.4 billion to 1.42 billion yuan, compared to 1.3435281 billion yuan in the previous year [1][5]. Stock Issuance - The company has decided to terminate the plan for a specific stock issuance for 2024, which was initially intended to raise up to 636 million yuan for various projects [1][5]. - The planned projects for the raised funds included the construction of new electrolyte materials, production of BPEF, BPF, and 9-fluorenone products, and a wastewater treatment center [2][5]. - The issuance was to involve up to 35 specific investors, including the controlling shareholder, Baiyun Group, and other qualified institutional investors [2][6]. Previous Fundraising - The company has previously raised funds through non-public stock issuances, totaling approximately 711.85 million yuan over the past five years [9]. - In 2019, the company raised approximately 270 million yuan through the issuance of 11,469,835 shares at a price of 23.54 yuan per share [3][7]. - In 2021, the company raised approximately 441.85 million yuan by issuing 25,914,956 shares at a price of 17.05 yuan per share [4][8].

证券代码：002915 证券简称：中欣氟材 公告编号：2025-002 浙江中欣氟材股份有限公司 第六届董事会第十九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 浙江中欣氟材股份有限公司（以下简称"公司"）第六届董事会第十九次会 议于 2025 年 1 月 17 日在浙江省绍兴市上虞区杭州湾上虞经济技术开发区经十三 路 5 号浙江中欣氟材股份有限公司研发中心一楼视频会议室以现场结合通讯表 决方式召开。会议通知以书面、邮件或电话方式于 2025 年 1 月 7 日向全体董事 发出。应出席董事 11 名，实际出席董事 11 名，其中，董事颜俊文先生和独立董 事倪宣明先生、杨忠智先生、袁康先生、苏为科先生以通讯表决的方式出席会议。 会议由董事长徐建国先生召集并主持，公司监事、高级管理人员列席了会议。 本次会议的通知、召集和召开符合《中华人民共和国公司法》和《浙江中欣氟材 股份有限公司章程》的规定，会议决议合法有效。 二、董事会会议审议情况 （一）审议并通过了《关于终止2024年度向特定对象发行股票事项的议案》 在综合考虑外部 ...

证券代码：002915 证券简称：中欣氟材 公告编号：2025-004 浙江中欣氟材股份有限公司 关于终止2024年度向特定对象发行股票事项的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江中欣氟材股份有限公司（以下简称"公司"）于 2025 年 1 月 17 日召开 第六届董事会第十九次会议和第六届监事会第十六次会议，审议通过了《关于终 止 2024 年度向特定对象发行股票事项的议案》，公司决定终止 2024 年度向特定 对象发行股票事项，现将有关情况公告如下： 一、2024 年度向特定对象发行股票的基本情况 公司于 2024 年 1 月 24 日分别召开第六届董事会第十三次会议、第六届监事 会第十一次会议，并于 2024 年 2 月 29 日召开了 2024 年第一次临时股东大会， 审议通过了《关于公司 2024 年度向特定对象发行股票方案的议案》等相关议案。 具体内容分别详见公司于 2024 年 1 月 25 日、2024 年 3 月 1 日在《证券时报》《证 券日报》《中国证券报》《上海证券报》和巨潮资讯网（http://www.cninfo ...

证券代码：002915 证券简称：中欣氟材 公告编号：2025-003 浙江中欣氟材股份有限公司 第六届监事会第十六次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 浙江中欣氟材股份有限公司（以下简称"公司"）第六届监事会第十六次会议 于 2025 年 1 月 17 日在浙江省绍兴市上虞区杭州湾上虞经济技术开发区经十三路 5 号浙江中欣氟材股份有限公司研发中心一楼视频会议室以现场表决方式召开。 会议通知以书面、邮件或电话方式于 2025 年 1 月 7 日向全体监事发出。应出席 监事 3 名，实际出席监事 3 名。 具体内容详见公司同日在《证券时报》《证券日报》《中国证券报》《上海 证券报》和巨潮资讯网（http://www.cninfo.com.cn）披露的《关于终止2024年度 向特定对象发行股票事项的公告》（公告编号：2025-004）。 （二）审议并通过了《关于公司与控股股东签订股份认购协议之终止协议 暨关联交易的议案》 鉴于公司决定终止 2024 年度向特定对象发行股票事项，公司与控股股东浙 江白云伟业控股集团有 ...